ANXA8

Across TCGA pan-cancer cohorts, ANXA8 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANXA8 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANXA8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANXA8 expression acts as an unfavorable survival marker.

PDAC, LSCC, and LUAD are the cancer types where ANXA8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.167	0.707	<.001	38	view →
LSCC	OS	Quartile	All	0.683	1.000	<.001	32	view →
LUAD	DFS	Median	II,III,IV	0.750	0.935	.024	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANXA8–PDAC (OS)

Open the PDAC breakdown →